SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segment Information

Financial information for the company’s segments is as follows.

	Three months ended				Nine months ended
	September 30,				September 30,
(in millions)	2017		2016		2017		2016
Net sales
Renal	$	1,010	$	977	$	2,874	$	2,840
Hospital Products		1,697		1,581		4,913		4,678
Total net sales	$	2,707	$	2,558	$	7,787	$	7,518
EBITDA
Renal	$	226	$	214	$	649	$	494
Hospital Products		653		588		1,821		1,673
Total segment EBITDA	$	879	$	802	$	2,470	$	2,167

EBITDA to Income from Continuing Operations Reconciliation

The following is a reconciliation of segment EBITDA to income from continuing operations before income taxes per the condensed consolidated statements of income.

	Three months ended						Nine months ended
	September 30,						September 30,
(in millions)	2017			2016			2017			2016
Total segment EBITDA	$	879		$	802		$	2,470		$	2,167
Reconciling items
Depreciation and amortization		(184	)		(204	)		(562	)		(599	)
Stock compensation		(31	)		(30	)		(77	)		(84	)
Net interest expense		(14	)		(14	)		(41	)		(53	)
Restructuring charges, net		(31	)		(130	)		(50	)		(237	)
Venezuela deconsolidation		—			—			(33	)		—
Net realized gains on Baxalta Retained Shares transactions		—			—			—			4,387
Net loss on debt extinguishment		—			(52	)		—			(153	)
Other Corporate items		(329	)		(244	)		(783	)		(753	)
Income from continuing operations before income taxes	$	290		$	128		$	924		$	4,675